Published in J Crohns Colitis on January 15, 2010
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (2015) 2.74
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12
Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci (2014) 2.03
Inflammatory Bowel Disease. Dtsch Arztebl Int (2016) 1.56
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Dig Dis Sci (2015) 1.51
Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci (2014) 1.41
Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol (2015) 1.29
Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci (2012) 1.27
Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol (2012) 1.21
Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol (2014) 1.19
Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol (2012) 1.15
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther (2015) 1.07
Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol (2012) 1.07
Crohn's disease in Korea: past, present, and future. Korean J Intern Med (2014) 1.06
Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol (2014) 1.03
Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol (2013) 1.03
Intestinal duplication in adulthood: A rare entity, difficult to diagnose. World J Gastrointest Surg (2011) 1.02
Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol (2011) 1.00
Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol (2013) 0.99
Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol (2015) 0.95
Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol (2012) 0.95
Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol (2016) 0.95
Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res (2015) 0.94
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther (2013) 0.93
Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol (2011) 0.92
Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol Res Pract (2013) 0.91
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci (2014) 0.91
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol (2015) 0.90
The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis (2011) 0.90
Use of thiopurines in inflammatory bowel disease. World J Gastroenterol (2013) 0.89
New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) (2014) 0.89
Role of capsule endoscopy Pillcam COLON 2 in patients with known or suspected Crohn's disease who refused colonoscopy or underwent incomplete colonoscopic exam: a case series. Tech Coloproctol (2013) 0.89
Clinical literature review of 1858 Crohn's disease cases requiring surgery in China. World J Gastroenterol (2015) 0.89
Surgery for inflammatory bowel disease in the era of laparoscopy. World J Gastroenterol (2013) 0.89
Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res (2014) 0.88
New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin Transl Immunology (2016) 0.87
Advances in nutritional therapy in inflammatory bowel diseases: Review. World J Gastroenterol (2016) 0.86
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One (2015) 0.86
Use of antibiotics in the treatment of Crohn's disease. World J Gastroenterol (2013) 0.86
Esophageal Crohn's disease treated "topically" with swallowed aerosolized budesonide. Case Rep Med (2010) 0.85
Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol (2014) 0.85
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol (2013) 0.85
Infliximab extends the duration until the first surgery in patients with Crohn's disease. Biomed Res Int (2013) 0.85
Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol Ther (2013) 0.84
Mechanisms, Management, and Treatment of Fibrosis in Patients with Inflammatory Bowel Diseases. Gastroenterology (2016) 0.83
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol (2011) 0.83
Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J (2014) 0.83
Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection. Clin Exp Immunol (2014) 0.83
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. Gastroenterol Res Pract (2015) 0.83
Local injection of infliximab in severe fistulating perianal Crohn's disease: an open uncontrolled study. Tech Coloproctol (2011) 0.83
Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. JMIR Mhealth Uhealth (2016) 0.83
The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.83
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn's disease. Tech Coloproctol (2015) 0.81
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol (2014) 0.81
A pilot study of transrectal endoscopic ultrasound elastography in inflammatory bowel disease. BMC Gastroenterol (2011) 0.81
Management of Crohn's disease - are guidelines transferred to clinical practice? United European Gastroenterol J (2015) 0.81
Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr (2013) 0.81
Current status of laparoscopic surgery for patients with Crohn's disease. Int J Colorectal Dis (2013) 0.81
Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients. World J Gastroenterol (2014) 0.80
Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol (2011) 0.80
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol (2015) 0.80
Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease. World J Gastroenterol (2012) 0.80
Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol (2013) 0.80
Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol (2012) 0.80
Endoscopic management of inflammatory bowel disease strictures. World J Gastrointest Endosc (2012) 0.80
Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis (2010) 0.80
Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. Dig Dis Sci (2014) 0.80
How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort. Int J Colorectal Dis (2014) 0.79
Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. Dig Dis Sci (2016) 0.79
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther (2016) 0.79
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis (2011) 0.79
Serial intralesional injections of infliximab in small bowel Crohn's strictures are feasible and might lower inflammation. United European Gastroenterol J (2014) 0.79
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ (2012) 0.79
TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm (2014) 0.79
Laparoscopic surgery in the management of Crohn's disease. World J Gastrointest Pathophysiol (2014) 0.79
Surgical management of IBD--from an open to a laparoscopic approach. Nat Rev Gastroenterol Hepatol (2013) 0.79
Parameters of a severe disease course in ulcerative colitis. World J Gastroenterol (2014) 0.79
Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol (2015) 0.79
Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract (2015) 0.79
Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy. Mol Diagn Ther (2016) 0.79
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol (2016) 0.78
Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol (2015) 0.78
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol (2016) 0.78
Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol (2014) 0.78
Prevalence of Mycobacterium avium subsp. paratuberculosis and Escherichia coli in blood samples from patients with inflammatory bowel disease. Med Microbiol Immunol (2015) 0.78
Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn's disease. BMC Res Notes (2014) 0.78
Current therapy of pediatric Crohn's disease. World J Gastrointest Pathophysiol (2015) 0.78
Patient perspectives on the impact of Crohn's disease: results from group interviews. Patient Prefer Adherence (2012) 0.78
Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. Dig Dis Sci (2015) 0.78
Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression. Clin Exp Immunol (2015) 0.78
Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients. World J Gastroenterol (2015) 0.78
Role of conventional therapies in the era of biological treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm (2015) 0.78
Training readers to improve their accuracy in grading Crohn's disease activity on MRI. Eur Radiol (2014) 0.77
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet (1987) 4.32
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
High frequency of early colorectal cancer in inflammatory bowel disease. Gut (2008) 3.46
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet (1996) 3.15
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 3.13
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther (2012) 2.87
Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci (1995) 2.75
Consensus on ventral rectopexy: report of a panel of experts. Colorectal Dis (2014) 2.72
Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. Endoscopy (2012) 2.58
[Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis]. Ned Tijdschr Geneeskd (2005) 2.57
Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg (2003) 2.54
Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 2.47
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun (2001) 2.28
Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology (1983) 2.23
Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2004) 2.23
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. BIS Utility Study Group. Anesthesiology (1997) 2.20
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis (2010) 2.17
Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition. Gastroenterology (1995) 2.16
An in-depth study of Crohn's disease in two French families. Gastroenterology (1993) 2.15
Helicobacter pylori: the cancer link. J R Soc Med (1996) 2.15
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther (2010) 2.12
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther (2014) 2.11
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother (1999) 2.07
Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut (2008) 2.06
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
Return of esophageal peristalsis after nifedipine therapy in patients with idiopathic esophageal achalasia. Am J Gastroenterol (1992) 2.02
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut (1997) 2.00
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther (2015) 2.00
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93
Elemental diets in treatment of acute Crohn's disease. Br Med J (1980) 1.92
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Nature meets nurture: molecular genetics of gastric cancer. Hum Genet (2009) 1.87
Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J Acquir Immune Defic Syndr (1991) 1.85
Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol (2002) 1.83
Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J Cell Biol (1989) 1.82
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Incidence of inflammatory bowel disease in northern France (1988-1990). Gut (1994) 1.81
Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol (2000) 1.79
Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology (1995) 1.77
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2014) 1.72
Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med (1997) 1.72
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology (1993) 1.71
Duodeno-jejunal adenocarcinoma as a first presentation of coeliac disease. J Clin Pathol (1996) 1.70